Stockscreener 앱 받기
7.96
3.28%
-0.27
시간 외 거래:
8.66
0.70
+8.79%
전일 마감가:
$8.23
열려 있는:
$8.23
하루 거래량:
2.02M
Relative Volume:
1.06
시가총액:
$1.04B
수익:
$727.33M
순이익/손실:
$-108.03M
주가수익비율:
-9.4313
EPS:
-0.844
순현금흐름:
$-21.78M
1주 성능:
-4.67%
1개월 성능:
+0.00%
6개월 성능:
-23.68%
1년 성능:
-16.91%
1일 변동 폭
$7.94
$8.60
1주일 범위
$7.94
$8.74
52주 변동 폭
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
명칭
Neogenomics Inc
전화
(239) 768-0600
주소
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.96 | 1.07B | 727.33M | -108.03M | -21.78M | -0.844 |
TMO
Thermo Fisher Scientific Inc
|
524.57 | 195.48B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
194.54 | 138.36B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.01 | 46.31B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
122.09 | 34.18B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
335.23 | 32.95B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-07-29 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | 개시 | Guggenheim | Neutral |
| 2025-04-30 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-12-10 | 개시 | Jefferies | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2023-12-29 | 재확인 | BTIG Research | Buy |
| 2023-08-21 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2023-02-24 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-02-01 | 업그레이드 | Needham | Hold → Buy |
| 2022-08-26 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-22 | 다운그레이드 | Needham | Buy → Hold |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-03-29 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-29 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | 재개 | Stephens | Overweight |
| 2021-12-16 | 개시 | Cowen | Outperform |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-02-25 | 재개 | Needham | Buy |
| 2021-02-25 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-12-11 | 재개 | BTIG Research | Buy |
| 2020-10-28 | 재확인 | Needham | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-08-28 | 개시 | Guggenheim | Buy |
| 2020-07-29 | 재확인 | Needham | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Buy |
| 2020-04-21 | 재개 | Stephens | Overweight |
| 2020-03-02 | 재개 | Craig Hallum | Buy |
| 2020-02-28 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | 재확인 | Needham | Buy |
| 2019-05-01 | 재확인 | Needham | Buy |
| 2019-03-29 | 재확인 | Needham | Buy |
| 2019-01-03 | 개시 | Needham | Buy |
| 2018-10-24 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | 개시 | Leerink Partners | Outperform |
| 2018-05-02 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2017-08-24 | 개시 | Gabelli & Co | Buy |
| 2016-12-15 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Neogenomics Inc 주식(NEO)의 최신 뉴스
NeoGenomics (NEO) Projected to Post Earnings on Tuesday - MarketBeat
NeoGenomics Inc stock (US64049M2098): Why does its oncology testing model matter more now? - AD HOC NEWS
NeoGenomics (NEO) Meets Q2 Earnings Estimates - MSN
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Performance Challenges - Markets Mojo
NeoGenomics (NASDAQ:NEO) Stock Price Down 5.3%Here's What Happened - MarketBeat
NeoGenomics to Spotlight AI-Driven Genomic–Clinical Data Integration at AACR 2026 - Clinical Lab Products
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will NeoGenomics Inc outperform the market in YEAR2026 Earnings Impact & Community Shared Stock Ideas - baoquankhu1.vn
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance
Guidance Update: Can NeoGenomics Inc deliver alpha2026 Chart Watch & Verified Momentum Stock Watchlist - baoquankhu1.vn
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 - National Today
Bearish Setup: Will NeoGenomics Inc stock hit new highs in YEAR2026 Historical Comparison & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Buybacks Report: Why is NeoGenomics Inc stock going up2026 Price Swings & Safe Swing Trade Setups - baoquankhu1.vn
Setup Watch: Can NeoGenomics Inc keep up with sector leaders2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Tudor Investment Corp ET AL Trims NeoGenomics, Inc. $NEO Stake - National Today
NeoGenomics, Inc. $NEO Stake Trimmed by Tudor Investment Corp ET AL - MarketBeat
Published on: 2026-04-09 16:25:20 - baoquankhu1.vn
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 - BioSpace
NeoGenomics to Report Q1 2026 Earnings on April 28 - National Today
NeoGenomics, Inc. (NEO) Stock forecasts - Yahoo Finance UK
NEOGENOMICS INC ($NEO) CEO 2025 Pay Revealed - Quiver Quantitative
NeoGenomics (NASDAQ: NEO) seeks approval to expand 2023 equity incentive plan - Stock Titan
Aberdeen Group plc Buys 1,006,676 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics | DEF 14A: Definitive information statements - Moomoo
NeoGenomics (NEO) COO nets shares after 17,562-unit RSU vesting - Stock Titan
NeoGenomics (NEO) CEO exercises RSUs and uses shares to cover taxes - Stock Titan
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles - AD HOC NEWS
NeoGenomics, Inc. (NEO) stock price, news, quote and history - Yahoo Finance UK
NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics - AD HOC NEWS
NEO|Neogenomics Inc|Price:7.995|Chg%:-0.00 - TradingKey
Growth Value: Why is NeoGenomics Inc stock going upWeekly Market Outlook & Capital Efficient Trade Techniques - baoquankhu1.vn
Geopolitics Watch: Will NeoGenomics Inc outperform the market in YEAR2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (NEO) Movement - Stock Traders Daily
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands - AD HOC NEWS
Loss Report: Should you buy the dip on NeoGenomics Inc2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
NeoGenomics Q2 2025 Earnings Preview - MSN
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. - National Today
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. $NEO - MarketBeat
GRI Bio (NASDAQ:GRI) versus NeoGenomics (NASDAQ:NEO) Financial Contrast - Defense World
Vanguard files 13G/A: NeoGenomics (NEO) ownership shows 0 shares - Stock Titan
Dip Buying: Whats the analyst consensus on NeoGenomics Inc2026 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NeoGenomics invites engagement on innovation in oncology at USCAP event - Traders Union
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Aug PreEarnings: Is NeoGenomics Inc stock a falling knife or bargain buyTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Retail: Is NeoGenomics Inc gaining market share2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Aug Chart Watch: Can NeoGenomics Inc deliver alpha2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
NEO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeoGenomics (NEO) launches RaDaR ST to capture share in $20B MRD market - msn.com
Discipline and Rules-Based Execution in NEO Response - Stock Traders Daily
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO) - simplywall.st
Neogenomics Inc (NEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.57%
0.03%
자본화:
|
볼륨(24시간):